- Home
- BDTX vs AGEN Comparison
BDTX vs AGEN Comparison
Compare BDTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- AGEN
- Stock Information
- Founded
- BDTX 2014
- AGEN 1994
- Country
- BDTX United States
- AGEN United States
- Employees
- BDTX N/A
- AGEN N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDTX Health Care
- AGEN Health Care
- Exchange
- BDTX Nasdaq
- AGEN Nasdaq
- Market Cap
- BDTX 181.4M
- AGEN 142.8M
- IPO Year
- BDTX 2020
- AGEN 2000
- Fundamental
- Price
- BDTX $3.16
- AGEN $4.55
- Analyst Decision
- BDTX Strong Buy
- AGEN Buy
- Analyst Count
- BDTX 6
- AGEN 2
- Target Price
- BDTX $12.50
- AGEN $14.50
- AVG Volume (30 Days)
- BDTX 840.0K
- AGEN 387.3K
- Earning Date
- BDTX 11-04-2025
- AGEN 11-11-2025
- Dividend Yield
- BDTX N/A
- AGEN N/A
- EPS Growth
- BDTX N/A
- AGEN N/A
- EPS
- BDTX 0.25
- AGEN N/A
- Revenue
- BDTX $70,000,000.00
- AGEN $101,706,000.00
- Revenue This Year
- BDTX N/A
- AGEN $60.49
- Revenue Next Year
- BDTX N/A
- AGEN N/A
- P/E Ratio
- BDTX $12.78
- AGEN N/A
- Revenue Growth
- BDTX N/A
- AGEN N/A
- 52 Week Low
- BDTX $1.20
- AGEN $1.38
- 52 Week High
- BDTX $6.23
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- BDTX 58.90
- AGEN 48.05
- Support Level
- BDTX $3.13
- AGEN $4.36
- Resistance Level
- BDTX $3.43
- AGEN $5.20
- Average True Range (ATR)
- BDTX 0.18
- AGEN 0.28
- MACD
- BDTX 0.02
- AGEN 0.05
- Stochastic Oscillator
- BDTX 63.51
- AGEN 40.91
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).